Charles McDermott
Kala Pharmaceuticals has appointed Charles McDermott to the role of executive VP, business development.
McDermott joins the company after eight years at Botox developers Allergan, and prior to that he was at deCODE Genetics in several business development positions.
CEO of Kala, Dr. Guillaume Pfefer, said: “We are rapidly gaining momentum within the ophthalmic industry and Charlie shares our vision to make a difference in the lives of patients suffering from ocular diseases.”